UpdatesMedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe FDA’s medical product safety reporting program for health professionals, patients and consumers. MedWatch receives reports from the public and when appropriate, publishes safety alerts for FDA-regulated products. The most recent alerts/recalls here:
Guidance DocumentsView all Official FDA Guidance Documents and other Regulatory Guidance
You can search for documents using key words, and you can narrow or filter your results by product, date issued, FDA organizational unit, type of document, subject, draft or final status, and comment period. FDA Voices| Like all drugs, sunscreens must meet rigorous standards for safety and efficacy. Because consumers rely on sunscreens as an essential part of cancer prevention and many people use them daily throughout their lives, it is critical to understand not only their protective benefits but also any potential risks from long-term use. |
ICYMI!Many people of all ages take medications. Keeping track of when, how and why you use medications is important for your health and safety. A medication list is a tool to help you keep track of all the prescription medications, over-the-counter (OTC) drugs, vitamins, and supplements that you take. Keeping a medication list helps health care professionals know about your current health and minimize medication errors and adverse drug interactions. It can be a lifesaving tool, especially during an emergency. Webinars and Virtual WorkshopsDay 1: Wed, Nov. 5, 2025; 9 a.m. - 4:30 p.m. ET
Day 2: Thu, Nov. 6, 2025; 9 a.m. - 4:30 p.m. ET
Day 3: Fri, Nov. 7, 2025; 9 a.m. - 4:30 p.m. ET
The purpose of the Cheminformatics Resources of U.S. Governmental Organizations 2025 Workshop is to enhance communication and collaboration between the U.S. Government-funded organizations that create and maintain databases, data standards, datasets, scientific approaches, and computational resources dealing with chemical structures and properties of molecules and materials. Date: Thu, Nov. 6, 2025; 9 a.m. - 6 p.m. ET
The FDA announces a forthcoming public advisory committee meeting of the Digital Health Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA. The meeting will be open to the public. The FDA is establishing a docket for public comment. Date: Fri, Dec. 5, 2025; 8 a.m. - 4 p.m. ET
The FDA in collaboration with the Triangle Center of Excellence in Regulatory Science and Innovation (Triangle CERSI) will host a public workshop entitled “Hybrid Public Workshop: Pediatric Developmental Safety Assessment and New Approach Methodologies” on December 5, 2025. The goal of this workshop is to discuss new approach methods that can address pediatric developmental safety during drug development. Day 1: Wed, Dec. 10, 2025; 1- 5 p.m. ET
Day 2: Thu, Dec. 11, 2025; 8:30 a.m. - 4:00 p.m. ET
The aim of the public workshop is to discuss common challenges in neonatal and rare disease product development and identify opportunities to leverage rare disease product development frameworks in the neonatal product development space. View Upcoming FDA Meetings, Conferences and Workshops
Public meetings involving the FDA: Upcoming events, past meetings, meeting materials, and transcripts About UsThe Public Engagement Staff resides within the Office of the Commissioner and falls under the Office of External Affairs. We aim to build stronger relationships with health professional organizations, patients and patient advocacy organizations, consumer groups, trade associations, think tanks and academia, and other interested parties, in order to better inform our policy making process, identify policy hurdles or misconceptions, and create strategic collaborations. For more information, please contact us at: PublicEngagement@fda.hhs.gov. For patient specific inquiries, please contact us at: Patients Ask FDA. |
